Carbone, M. et al. J Thorac Oncol 17, 873-889 (2022)
Archives: Publications
Publications
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Kindler, H. L. et al.. Lancet Oncol 23, 540-552 (2022).
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
Fennell, D. A. et al. Lancet Oncol 23, 374-381 (2022).
Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
Fennell, D. A. & Dulloo, S. J Thorac Oncol 17, 34-37 (2022).
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Fennell, D. A. et al. Lancet Oncol 22, 1530-1540 (2021).
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
Aliagas, E. et al. Br J Cancer 125, 1365-1376 (2021).
Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes, S. M., Alrifai, D. & Fennell, D. A. N Engl J Med 385, 1207-1218 (2021).
Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
Harber, J., Kamata, T., Pritchard, C. & Fennell, D. J Immunother Cancer 9 (2021).
CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition
Pinton, G. et al. Front Oncol 11, 678447 (2021).
Precision Therapy for Mesothelioma: Feasibility and New Opportunities
Dulloo, S., Bzura, A. & Fennell, D. A. Cancers (Basel) 13 (2021).